Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma

Journal of the American College of Surgeons

Volumn 199, Issue 1, 2004, Pages 78-86

  Streck, Christian J ^a,b   Zhou, Junfang ^a   Ng, Catherine Y ^a   Zhang, Youbin ^a   Nathwani, Amit C ^c   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AAV; adeno associated virus; hFIX; human clotting factor IX; NB; neuroblastoma; rAAV; recombinant adeno associated virus; SCID; severe combined immunodeficiency; truncated, soluble fetal liver kinase 1; tsFlk 1; vascular endothelial growth factor; VEGF; VEGFR

Indexed keywords

PARVOVIRUS VECTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; INJECTION SITE; LIVER METASTASIS; MICROVASCULATURE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TRANSGENE;

EID: 3042653369     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2004.02.011     Document Type: Article

References (38)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:1992;65-71
2. Bicknell R., Harris A.L. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol. 8:1996;60-65
3. Pluda J.M. Tumor-associated angiogenesis mechanisms, clinical implications, and therapeutic strategies. Semin Oncol. 24:1997;203-218
4. Folkman J., Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 3:1992;89-96
5. Bicknell R., Harris A.L. Anticancer strategies involving the vasculature vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol. 3:1992;399-407
6. Scott P.A., Harris A.L. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev. 20:1994;393-412
7. Kerbel R.S., Yu J., Tran J., et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20:2001;79-86
8. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA. 95:1998;9064-9066
9. Kong H.L., Crystal R.G. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst. 90:1998;273-286
10. Lau K., Bicknell R. Antiangiogenic gene therapy. Gene Ther. 6:1999;1793-1795
11. Kleinman H.K., Liau G. Gene therapy for antiangiogenesis. J Natl Cancer Inst. 93:2001;965-967
12. Slaton J.W., Perrotte P., Inoue K., et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 5:1999;2726-2734
13. Nguyen J.T., Wu P., Clouse M.E., et al. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58:1998;5673-5677
14. Kaplitt M.G., Leone P., Samulski R.J., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 8:1994;148-154
15. Herzog R.W., Hagstrom J.N., Kung S.H., et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:1997;5804-5809
16. Nathwani A.C., Davidoff A., Hanawa H., et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 97:2001;1258-1265
17. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1995;1029-1039
18. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309
19. Ferrara N., Heinsohn H., Walder C.E., et al. The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci. 752:1995;246-256
20. Millauer B., Shawver L.K., Plate K.H., et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579
21. Lin P., Sankar S., Shan S., et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9:1998;49-58
22. Davidoff A.M., Leary M.A., Ng C.Y., et al. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg. 36:2001;30-36
23. Davidoff A.M., Nathwani A.C., Spurbeck W.W., et al. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res. 62:2002;3077-3083
24. Matthay K.K. Neuroblastoma a clinical challenge and biologic puzzle. CA Cancer J Clin. 45:1995;179-192
25. Nathwani A.C., Davidoff A.M., Hanawa H., et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood. 100:2002;1662-1669
26. Davidoff A.M., Ng C.Y., Brown P., et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res. 7:2001;2870-2879
27. Weidner N., Folkman J., Pozza F., et al. Tumor angiogenesis a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1992;1875-1887
28. Herbst R.S., Mullani N.A., Davis D.W., et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 20:2002;3804-3814
29. Thompson J., Guichard S.M., Cheshire P.J., et al. Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol. 47:2001;211-221
30. Gerber H.P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 81:2003;20-31
31. Eggert A., Ikegaki N., Kwiatkowski J., et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 6:2000;1900-1908
32. Davidoff A.M., Leary M.A., Ng C.Y., et al. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med Pediatr Oncol. 35:2000;638-640
33. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221-228
34. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 5:1999;434-438
35. Asahara T., Takahashi T., Masuda H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:1999;3964-3972
36. Crosby J.R., Kaminski W.E., Schatteman G., et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 87:2000;728-730
37. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-XI. Science. 302:2003;415-419
38. Berger A.C., Feldman A.L., Gnant M.F., et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res. 91:2000;26-31